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Abstract Primary PCI of infarct-related arteries is the pre-
ferred reperfusion strategy in patients presenting with ST-
segment elevation myocardial infarction (STEMI). Up to
40 % of such patients demonstrate evidence of multivessel,
non-infarct-related artery coronary disease. Previous non-
randomised observational studies and their associated
meta-analyses have suggested that in such cases only the
culprit infarct-related artery (IRA) lesion should be treated.
However, recent randomised controlled trials have demon-
strated improved clinical outcomes with lower major ad-
verse cardiovascular events (MACE) rates when complete
revascularisation is undertaken either at index primary per-
cutaneous coronary intervention (PPCI) or during index
admission. These trials suggest that current guidelines
pertaining to treatment of non-infarct-related artery (N-
IRA) lesions in STEMI patients with multivessel disease
may need to be reconsidered depending on future trials.
However, issues remain around timing of N-IRA interven-
tion, the use of fractional flow reserve (FFR) or intravas-
cular imaging to guide intervention in N-IRA lesions and
the need to demonstrate reductions in hard clinical end-
points (death and MI) after complete revascularisation;
these issues will need to be addressed through future trials.
Clinicians must judge on the currently available data,
whether it is still safer to leave important stenosis in N-
IRA untreated.
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Introduction
Primary percutaneous coronary intervention (PPCI) is the
preferred reperfusion strategy in ST-segment elevation
myocardial infarction (STEMI). It is estimated that 40 %
of patients who present with STEMI have multivessel dis-
ease at index angiography [1–4]. How such significant le-
sions in the non-infarct-related vessels should be treated is
controversial. There is evidence to suggest such patients
have worse long-term outcomes compared to patients pre-
senting with single-vessel disease, including a need for
repeat revascularisation and repeat admissions with MI
[5, 6]. However, undertaking PCI in by-stander lesions
during STEMI can have potential complications. Current
guidelines from the ACC/AHA [7] and ESC [8] recom-
mend treatment of the culprit artery only in the absence
of haemodynamic compromise.
The aim of this article is to review the current data
pertaining to management of non-culprit lesions in patients
presenting with ST elevation myocardial infarction, as well
as some of the current guideline recommendations and the
remaining outstanding questions regarding management of
these lesions.
This article is part of the Topical Collection on Management of Acute
Coronary Syndromes
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Non-Randomised Studies and Current Guideline
Recommendations
Much of the initial evidence base pertaining to complete
revascularisation in STEMI patients with multivessel disease
came from non-randomised observational cohort studies and
registry data (Table 1; 9–19, 21–24). These observational
studies contain some potential confounding factors, such as
cardiogenic shock within the groups treated with complete
revascularisation that may influence the outcome measures
[24].
A meta-analysis of early observational and randomised
studies [25•] showed benefit in longer-term mortality with
complete revascularisation if non-infarct-related artery (N-
IRA) PCI is performed on a staged basis as opposed to being
undertaken the time of the index PCI.
A separate meta-analysis by Bangalore et al. included 19
studies (2 randomised studies, 17 observational or registry
studies) to evaluate early (<30 days) and long-term safety
and efficacy of multivessel PCI [26]. Of the 61,764 patients
included, multivessel PCI was performed in only 9690 (16 %)
of patients with the remaining 84 % undergoing culprit lesion
only PCI. Overall there was no significant difference in 30-
day mortality (OR=1.04, 95 % CI=0.93–1.15); however,
when stratified by timing of intervention, 30-day mortality
was lower with the complete revascularisation when N-IRA
PCI was performed as a staged procedure (OR=0.44, 95 %
CI=0.33–0.59), while there was a trend towards worse 30-day
mortality if N-IRA PCI was performed at the same time as the
culprit PPCI (OR=1.19, 95 % CI=1.06–1.34). Longer-term
mortality (>1 year post-primary PCI) was significantly lower
with complete revascularisation (OR=0.67, 95 % CI=0.58–
0.79) and again, this effect was attenuated if complete
revascularisation was undertaken at the same sitting as prima-
ry PCI of the culprit lesion (OR=0.91, 95 % CI=0.73–1.14).
A 30-day and longer-term major adverse cardiovascular event
(MACE) was signif icant ly lower with complete
revascularisation regardless of when the N-IRA PCI was un-
dertaken. There was a high degree of heterogeneity seen
amongst the studies within this meta-analysis, particularly in
those where complete revascularisation was undertaken at the
same sitting.
A propensity-matched analysis of 3984 patients with
STEMI and multivessel disease presenting in eight cardiac
centres within London between 2004 and 2011 looked at out-
comes from culprit-only and complete revascularisation at
time of PPCI [27]. Cardiogenic shock and LMS disease was
excluded from the analysis. In this cohort, 555 patients, i.e.
13.9 % of patients with multivessel disease, underwent
multivessel PCI. Although propensity-matched analysis sug-
gested an improved survival with culprit-only PCI during the
index procedure (HR=0.64; 95 % CI=0.45–0.90; P=0.010)
and reduced MACE with culprit-only PCI (HR=0.49; 95 %
CI=0.32–0.76; P=0.002), there are some important limita-
tions to this study. Specifically, it could not be ascertained
how many patients in the culprit-only cohort went on to have
staged complete revascularisation. Secondly, presence of car-
diogenic shock was based on use of inotropes and IABP in
cases as no haemodynamic data were available, hence it is
possible a proportion of the patients undergoing multivessel
disease had early cardiogenic shock prior to receiving com-
plete revascularisation.
The question has been raised as to the potential downsides
of leaving a non-infarct-related artery untreated. In a retro-
spective analysis of 28,282 STEMI patients, it was shown that
the presence of multivessel disease (52.8 %) appeared to con-
fer a worse prognosis, with the presence of N-IRA disease
being significantly associated with 30-day mortality (unad-
justed, 4.3 vs 1.7 %, respectively; risk difference,
2.7 %[95 % CI=2.3–3.0 %], P<.001; and adjusted, 3.3 vs
1.9 %, respectively; risk difference, 1.4 % [95 % CI=1.0–
1.8 %], P<.001) [28].
The 2012 ESC guidelines on STEMI management recom-
mend BPCI should be limited to the culprit vessel with the
exception of the presence of cardiogenic shock and persistent
ischaemia after PCI of the supposed culprit lesion^ (Class IIa
recommendation, Level of evidence B) [7]. Prior to the pub-
lication of recent randomised studies, in 2013 the ACCF/AHA
guidelines give PCI to an non-infarct-related artery at the time
of primary PCI without haemodynamic instability a class III
recommendation (Level of evidence B) [8]. These recommen-
dations are largely drawn on the preceding non-randomised
studies and meta-analyses as outlined above.
Randomised Studies
Two recently reported UK-based RCTs comparing culprit-
only revascularisation to treatment of any trial-defined signif-
icant additional non-IRA in STEMI with multivessel disease
have opened a debate as to how these patients might be
managed.
PRAMI was a randomised open trial that recruited 465
patients over 4 years, who presenting with STEMI were found
to havemultivessel coronary disease [29••]. The study defined
the presence of multivessel disease as a non-infarct-related
artery (N-IRA) lesion >50 % stenosis within a major epicar-
dial artery. Patients recruited to the study were randomised to
receive either culprit-only PCI or PCI of both culprit and N-
IRA lesions at the same sitting (i.e. during index primary PCI
procedure). The primary outcomemeasure was a composite of
cardiovascular death, newMI and refractory angina defined as
angina despite medical therapy supported by evidence of ob-
jective ischaemia The study was discontinued early by the
DSMB at a mean follow-up of 23 months, due to a significant
difference in primary endpoint in favour of complete
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Table 1 Summary of non-randomised studies comparing complete and culprit-only revascularisation in STEMI patients
Study Description Exclusion criteria Outcome measures.
Abe et al. 2012
[9]
Retrospective cohort study. 274 STEMI
patients with multivessel disease
undergoing culprit-only PCI (n=220) or
multivessel PCI (n=54). Median follow-up
of 374 days.
Increased risk of in-hospital death: 5.45 % vs
20.4 %, P<0.05; all-cause death: 10.9 %
vs 31.5 %, P<0.05 and MACE: 27.7 % vs




Retrospective analysis of the NCDR database
from 2004 to 2007 of patients undergoing
primary PCI for STEMI. N=28,936;
10.8 % underwent multivessel PCI
(n=3134).
Staged PCI treatment Overall in-hospital mortality greater in
patients with multivessel PCI (7.9 % vs.
5.1 %, P<0.01). IN patients with STEMI
and Cardiogenic shock, MV-PCI resulted
in increased in-hospital mortality (36.5 %
vs. 27.8 % for culprit-only, adjusted
OR=1.5, 95 % CI=1.22–1.95)
Chen et al.,
2005 [11]
Retrospective analysis of patients presenting
with AMI (STEMI and NSTEMI) and
evidence of multivessel disease. N=1384;
culprit-only PCI- n=1189, multivessel PCI




No difference in 1-year survival (MV-
PCI=0.93, 95 % CI=0.87–0.95, culprit-
only PCI=0.92, 95 % CI=0.92–0.95,
P=0.93) or 1 year survival from MI and





Retrospective analysis of 506 patients
presenting with STEMI and multivessel
disease, undergoing culprit-only PCI
(n=354), PCI of IRA+N-IRA during same
procedure (n=26), PCI of IRA and N-IRA
during index admission (n=126).
PCI to SVG, LMS, acute
occlusion after angioplasty
or staged OP procedure.
MV-PCI associated with higher rate of
reinfarction (13.0 % vs, 2.8 %, P<0.001),
revascularisation (25 % vs. 15 %,





Retrospective analysis of 1598 STEMI
patients. 777 patients with MVD, 70
underwent MV-PCI, 707 culprit-only.
Higher rate of 30-day death, MI and
revascularisation (adjusted OR=1.33,
95 % CI=0.57=3.10, P=0.51), bleeding
adjusted (OR=0.80, 95 % CI=0.32–2.02,
P=0.64) and 1 year death (adjusted




N=242. Retrospective analysis. 192 patients
underwent PCI to IRA-only, 93 patients





No significant difference in 12-month MACE
(11.5 % vs 15.1 %, P>0.05) or target
lesion revascularisation (8.1 % vs 7.6 %,
P>0.05). Higher rates of recurrent angina




Registry of 3251 patients undergoing either
culprit-only PCI, PCI at time of index
procedure and staged (within 60 day) PCI
to N-IRA lesions. Propensity-matched
analysis.
Shock, previous heart surgery,
LMS disease, thrombolysis
Non-significant trend towards higher in-
hospital, 12- and 42-month mortality in
MV-PCI undertaken at time of index
procedure compared with culprit-only PCI.
Significant in-hospital mortality excess
with index procedure MV-PCI compared to
culprit-only PCI when haemodynamic
instability excluded. Lower 12-month
mortality with stagedMV-PCI compared to




Prospective study of 73 STEMI patients, with
MV-PCI undertaken in the first 28 patients
and culprit-only PCI with either planned
staged or ischaemia-driven PCI of N-IRA
lesions in 45 patients.
Similar baseline characteristics. MACE
(death, MI and TVR) at 12 months similar
between the two treatment strategies (MV-
PCI=24 %, culprit-only=28 %, P=0.73).
No difference in revascularisation (MV-





Analysis of 668 STEMI patients from the
HORIZONS-AMI trial, undergoing either
same-setting MV-PCI (n=275) or staged




Higher rates of 1-year mortality, cardiac
mortality and definite/probable stent
thrombosis in patients undergoing same-
setting MV-PCI compared to staged PCI.
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revascularisation (HR=0.35, 95 % CI=0.21–0.58, P<0.001)
having been reached. In particular, this appeared to be driven
primarily by a significant reduction in refractory angina (HR=
0.35, 95 % CI=0.13–0.75) and non-fatal myocardial
infarction (HR=0.32, 95 % CI=0.13–0.75), although no sig-
nificant reduction in mortality was shown. The randomisation
process was not stratified for timing of intervention in relation
to symptom onset, nor for site of infarction. Indeed, the
Table 1 (continued)
Study Description Exclusion criteria Outcome measures.
characteristics between groups, except
higher rates of TIMI0/1 flow in culprit
vessel in staged PCI group.
warfarin, bleeding
diathesis, transfusion.
Single-setting MV-PCI was independently
predictive of 30-day and 1-year mortality
and MACE (death, reinfarction, TVR and
stroke).
Lee et al., 2012
[18]
1644 STEMI patients from Korean registry
with multivessel disease undergoing
culprit-only (n=1106) or multivessel PCI
(n=538). Lower incidence of 3vD in
culprit-only group, higher number of
patients with EF <40 % in culprit-only
group.
No significant difference in MACE (all-cause
death, MI, revascularisation, CABG) at
30 days or 12 months between the two
groups. Higher rate of TLR in MV-PCI




2061 STEMI patients with multivessel
disease undergoing PPCI; 706 culprit-only,
367 multivessel index procedure, 988
staged PCI at 60 days.
Shock, CTO in one vessel,
severe LMS, previous
CABG
Multivariate analysis showed higher rates of
30-day and 2-year mortality in culprit-only
PPCI compared to staged MV-PCI. Short-
term mortality rates higher for multivessel
PCI compared to culprit PPCI.
Quarani et al.
2008. [20]
Prospective non-randomised study of 120
consecutive patient presenting with STEMI
and multivessel disease underwent either




Reduction in in-hospital MACE events (in-
hospital mortality, recurrent ischaemia,
reinfarction, acute heart failure) with
complete revascularisation (16.7 % vs
52 %, P=0.001), driven by reductions in
recurrent ischaemia, reinfarction and acute




Retrospective comparison of STEMI patients
with multivessel PCI undergoing culprit-





Non-significantly Higher in-hospital MACE
with complete revascularisation (20.3 %
vs. 10.8 %, P=0.186), driven by
periprocedural MI. Lower follow-up
MACE events with staged MV-PCI.
Roe et al.,
2001. [22].
Retrospective study of 68 cases of multivessel
PCI at time of IRA-primary PCI, matched
to 61 cases of primary PCI IRA-only PCI.
IN the primary PCI subgroup analysis:
MACE higher in MV-PCI (35.3 % vs.
27.9 %, P=0.63). Significantly higher risk
of stroke with MV-PCI (10.3 % vs 0 %,
P=0.01) and non-significantly increase 6-
month mortality and reinfarction.
Toma et al.
2010 [23].
Retrospective analysis of 2201 STEMI
patients withMVD in the APEX-AMI trial;
217 underwent N-IRA PCI, 1984
underwent IRA-PCI alone.
90-day death rate significantly higher in N-
IRA PCI group (12.5 % N-IRA; 5.6 %
IRA-only, P (log rank) <0.001). 90-day
composite of 90-day death, CHF and shock




Retrospective study of 399 patients with
STEMI and MVD (IRA-only=156, MV-
PCI at index procedure=147, MV-PCI
staged pre discharge=96).
After exclusion of patients with cardiogenic
shock and pulmonary oedema (seen more
often in index procedure MV-PCI); MV-
PCI 30 day mortality=2.8 %, IRA-
only=6.3 %. Rate of MV-PCI similar to
STEMI patients with single-vessel disease
in this cohort. No difference in 30-day
mortality between single-setting and staged
procedure for N-IRA lesion
Abbreviations:MV-PCImultivessel percutaneous coronary intervention,MACEmajor adverse cardiovascular events (as defined in each study), LMS left
main stem, IRA infarct-related artery, N-IRA non-infarct-related artery, MI myocardial infarction, STEMI ST elevation myocardial infarction, CTO
chronic total occlusion, SVG saphenous vein graft, MVD multivessel disease
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infarct-related artery (IRA)-only group in this study demon-
strated a higher proportion of diabetic patients and those ad-
mitted with anterior MI, both known to confer worse progno-
sis following acute myocardial infarction.
CvLPRIT was a second open randomised trial comparing
culprit lesion only with complete intervention in patients pre-
senting with STEMI and evidence of multivessel disease
[30••]. N-IRA lesions were defined as those being >70 %
diameter stenosis. A total of 296 patients were recruited to
the study over a similar timeframe as PRAMI. Patients were
randomised to e i the r comple t e o r cu lp r i t -on ly
revascularisation following confirmation on index angiogra-
phy of one or more N-IRA lesions. In this study, the N-IRA
PCI could be undertaken either at the time of index primary
PCI to the culprit, or on a separate occasion but within the
same admission. Like PRAMI, this trial showed a reduction in
the primary endpoint of death, MI, heart failure and
ischaemic-driven revascularisation with complete
revascularisation (HR=0.45, 95 % CI=0.24–0.84, P=
0.009). Within the components of the primary endpoint, while
showing a trend towards lower adverse events with complete
revascularisation, none of the individual components of the
primary endpoint attained statistical significance. In addition,
there was a very early separation of the Kaplan-Meier event
curves between the two randomised groups, suggesting an
early benefit with complete revascularisation. As with
PRAMI, the trial had small number of events in both arms,
and the open-label nature of the study may have an impact on
revascularisation in patients with known untreated N-IRA le-
sions in the culprit-only group.
Subsequent important contributions to the evidence base
include the Third DANish Study of Optimal Acute Treat-
ment of Patients with ST-segment Elevation Myocardial
Infarction. The PRImary PCI in MULTIvessel Disease
(DANAMI3-PRIMULTI) trial [31] recently reported and
was a randomised trial recruiting 627 patients from a cohort
of 2239 patients who had initially been randomised to the
Bischaemic post-conditioning (iPOST)^ or Bdeferred
stenting (DEFER)^ other arms of the study, and in whom
there was evidence of multivessel disease with successful
primary PCI of the IRA. The patients were then randomised
to receive either fractional flow reserve (FFR)-guided in-
tervention of N-IRA lesions, or medical management with
no further intervention. The primary endpoint was compos-
ite of all-cause mortality, non-fatal myocardial infarction
and ischaemic-driven revascularisation of N-IRA lesions.
As with CvLPRIT and PRAMI, this study also showed
benefit in favour of complete revascularisation (HR=0.56,
95 % CI=0.38–0.83, P=0.004); however, there was no sig-
nificant difference in all-cause mortality nor in non-fatal
myocardial infarction between the two groups the reduction
in composite endpoint being primarily driven by a reduced
rate of ischaemic-driven revascularisation in the FFR-
guided complete revascularisation group (HR=0.31, 95 %
CI=0.18–0.53, P<0.001).
PRAGUE-13 randomised 214 STEMI patients with
multivessel disease to either complete revascularisation be-
tween 3 and 40 days post PPCI or IRA-PCI only [32]. This
trial demonstrated no difference in MACE (death/MI/CVA)
between the two groups (HR=1.36, 95 % CI=0.66–2.74).
However, the severity of N-IRA lesions was less than in other
studies, with only 6.1 % of N-IRA lesions being classed as
>95 % stenosis. This study did not include ischaemia-driven
revascularisation as part of the endpoint and was underpow-
ered to detect differences in hard endpoints. It is generally
regarded as a trial of less significant non-IRA lesions.
In 2014, PRAMI and CvLPRIT led to the ACC withdraw-
ing a Bdo-not-do^ recommendat ion of comple te
revascularisation in STEMI patients with multivessel disease.
The results of these trials and associate meta-analyses suggest
that the current guideline recommendations pertaining toman-
agement of multivessel disease in STEMI should be revisited.
Safety of Complete Revascularisation
Performing complete revascularisation has been shown to re-
sult in greater use of contrast, prolonged procedural time and
increased exposure to radiation especially when performed at
the same time as the index primary PCI for the culprit lesion
[29••, 30••, 31, 33]. In spite of this, a pooled analysis of
PRAMI, CvLPRIT and the trial by Politi et al. has shown no
increase in CVA, bleeding or contrast-induced nephropathy
[34•]. Thus, the data suggest, although procedure times and
con t r a s t u s e may be inc r e a s ed w i t h comp l e t e
revascularisation, this does not translate to an increased risk
of adverse events. Similarly, there was no difference in rates of
periprocedural MI, stroke, contrast-induced nephropathy or
bleeding between the two revascularisation strategies in the
DANAMI3-PRIMULTI study [31].
Is There a Prognostic Benefit for Complete
Revascularisation?
Although the recent RCTs demonstrate a benefit of composite
MACE endpoints with complete revascularisation, in
CvLPRIT and DANAMI3-PRIMULTI, this has mainly been
driven by a reduction in ischaemia-driven revascularisation
within the complete revascularisation arm. In PRAMI, a re-
duction in refractory angina and non-fatal myocardial infarc-
tion was seen; however, ischaemia-driven revascularisation
(in this study as a secondary endpoint) was also reduced.
However, none of these trials were adequately powered to
detect a difference in prognostic clinical endpoints of death
or myocardial infarction.
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A meta-analysis of four RCTs that compared culprit-only
and complete revascularisation (CvLPRIT, PRAMI, Politi and
HELP-AMI) consisting of 1044 randomised patients demon-
strated significant reduction in long-term (≥1 year) all-cause
mortality (RR: 0.57, 95 % CI=0.36–0.92, P=0.02), cardio-
vascular death (RR: 0.38, 95 % CI=0.20–0.73, P=0.004) and
myocardial infarction (RR: 0.41, 95 % CI=0.23–0.75; P=
0.004) with complete revascularisation compared to culprit-
only PCI. In all three analyses, there was a low degree of
heterogeneity between the included studies [34•]. There was
a low degree of heterogeneity between the included studies
(I2=0 % for all three outcome measure comparisons).
Similarly, meta-analyses described below including both
randomised trials and non-randomised studies have demon-
strated a reduction in long-termmortality rates when complete
revascularisation is performed as a staged procedure (i.e. not
at the index primary PCI procedure) [25•, 35].
While the above meta-analyses indicate a signal towards
improved death and MI with complete revascularisation, they
are limited by the design limitations of the individual studies
and also the heterogeneity between the studies in terms of
inclusion and exclusion criteria, timing of the N-IRA proce-
dures and outcomemeasures. Hence, this question can only be
answered robustly by appropriately powered randomised tri-
als with sufficient numbers to detect any differences in death
and MI between strategies.
Timing of Complete Revascularisation
An issue not fully addressed by the recent randomised trials is
the optimal timing of complete revascularisation. Mechanisti-
cally, performing complete revascularisation at the time of
culprit primary PCI could potentially lead to extension of in-
farcted muscle if the attempted PCI to the N-IRA were to be
complicated by coronary dissection or stent thrombosis, so-
called double jeopardy.
Potential timing for complete revascularisation include un-
dertaking it at the time of index primary PCI, as a separate
procedure during the index admission, or as a planned elective
outpatient procedure for the N-IRA lesions.
Hannan et al. (2010) published registry data of multivessel
disease in STEMI undergoing primary PCI between Jan 2003
and June 2006 [15]. A total of 3521 patients were included, of
whom 259 underwent staged PCI during the index admission,
and 538 underwent staged intervention of N-IRA lesions with-
in 60 days of discharge from index admission. Patients with
shock, previous heart surgery, LMS disease or thrombolysis
prior to PCI were excluded. Propensity matching was under-
taken for comparison of inpatient, mortality between culprit-
only PCI, complete revascularisation during index procedure
and staged complete revascularisation as defined above.
This study showed in patients without features of haemo-
dynamic instability, increased in-hospital mortality occurred
with complete revascularisation at index procedure compared
to culprit-only (complete revascularisation at time of index
PCI=2.4 %, culprit-only PCI=0.9 %, P=0.04).
There was however a difference in 12-month mortality in
favour of complete revascularisation when undertaken as a
staged procedure within 60 days compared to culprit-only
PCI (staged complete revascularisation=1.3 %, culprit-only
PCI=3.3 %, P=0.04). Overall, the findings from this registry
data indicate that a potential mortality benefit was present if
N-IRA PCI was performed as a staged procedure and also
suggested potentially worse outcomes by complete
revascularisation at the time of the index procedure.
A meta-analysis of randomised and non-randomised stud-
ies [25•] suggests that index procedure complete
revascularisation may be associated with increased in-
hospital morality, while performing staged complete
revascularisation was associated with reduced in-hospital
mortality (OR 0.35, 95 % CI=0.21–0.59; P<.001; P interac-
tion <.001). The same meta-analysis also showed reduced
longer-term mortality with complete revascularisation (OR
0.74, 95 % CI=0.65–0.85, P<.001) and repeat PCI (OR
0.65; 95 % CI=0.46–0.90, P=.01 [randomised OR 0.31,
95 % CI=0.17–0.57, P<.001; non-randomised OR 0.88,
95 % CI=0.59–1.31, P=.54]).
A paired and network meta-analysis of 14 studies in-
cluding 40,280 patients, compared three timing strategies
in STEMI patients with multivessel disease; staged PCI,
(defined in this analysis as separate procedure either during
index admission or within 1 month of the primary PCI),
complete revascularisation during index primary PCI pro-
cedure, and culprit-only PCI. This analysis showed lowest
short- and long-term mortality rates in patients undergoing
staged complete revascularisation [35]. The majority of the
studies within this analysis were retrospective cohort stud-
ies, and although in some cardiogenic shock were exclud-
ed, given that for retrospective studies the decision to per-
form either index procedure or staged complete
revascularisation was not prospectively registered, the
analysis could not fully adjust for any important patient
characteristics that may have influenced the decision for
index procedure complete revascularisation.
While the above studies suggest deferring N-IRA PCI to a
staged procedure, data from the randomised studies with re-
gard to timing of the intervention do not support this strategy.
The Politi study [33] randomised patients to receive either
inpatient, staged outpatient complete revascularisation or
culprit-only revascularisation. This showed lower rates of
MACE with complete revascularisation compared to culprit-
only; however, there appeared to be no difference in MACE
event rates between inpatient and staged outpatient complete
revascularisation.
75 Page 6 of 10 Curr Cardiol Rep (2015) 17: 75
The CvLPRIT study suggested that there may be benefit
from early intervention, with a landmark analysis of the data at
30 days showing a trend towards improved early MACE re-
duction with complete revascularisation (HR=0.45, 95 %
CI=0.19–1.04, P=0.055). Although this did not achieve sta-
tistical significance, there is a clear early separation in the
Kaplan-Meier curves for MACE. A subsequent analysis of
the 139 patients who underwent complete revascularisation
within the study showed no difference in the 12-month prima-
ry composite MACE endpoint (death/MI/HF/repeat
revascularisation) between complete revascularisation at the
index procedure compared with staged inpatient
revascularisation (6.2 % index complete vs. 11.9 % staged
inpatient; HR=0.51, 95 % CI=0.16–1.67, P=0.29). Although
when looking at composite of death/MI/HF, there was a non-
significant trend towards lower rates with index procedure
complete revascularisation (3.1 vs. 11.9 %; HR=0.26, 95 %
CI=0.06–1.08, P=0.06). These post-hoc analysis results have
to be interpreted with caution as the patients were not
randomised to performing either index procedure or staged
inpatient complete revascularisation. .
Comparison of index procedure and staged outpatient com-
plete revascularisation was also examined in a randomised
trial by Ochala et al. [36]. In this study, 98 patients were
randomised to receive either one-stage (index procedure) or
two-stage (elective outpatient) complete revascularisation.
Cardiogenic shock and LMS >50 % were excluded from the
study. There was no difference in MACE (defined as all-cause
death, MI, urgent revascularisation) or improvement in LVEF
between the 2 groups, with staged revascularisation of N-IRA
lesions performed 27.3±12.8 days after primary PCI.
When N-IRA PCI should be performed remains an issue
for further research in adequately powered studies.
Assessing the Significance of Non-culprit Lesions:
Functional vs. Anatomical vs. Plaque Composition
Most of the observational and randomised studies have used
angiographic diameter stenosis severity to determine N-IRA
lesions requiring treatment. However, it is known within the
context of stable angina assessment that determining the hae-
modynamic significance of lesions using fractional flow re-
serve may allow for more accurate identification of lesions
requiring intervention.
Ntaliansis et al. showed that amongst 75 STEMI patients,
there was no significant change in the FFR measurement in
the non-IRAwhen repeated at a mean of 35±4 days post initial
procedure (0.78±0.10 vs. 0.76±0.10, P=NS) [37].
Preliminary data from the COMPARE-ACUTE study also
suggest a disparity between angiographic-determined signifi-
cance and haemodynamically significant N-IRA lesions in
STEMI patients. In 408 STEMI patients with evidence of
multivessel disease defined by presence of N-IRA lesions with
diameter stenosis of >50 %, FFR measurements performed at
the time of index procedure showed that in 56.5 % the FFR
was negative (<0.8) [38].
Dambrink et al. randomised 121 STEMI patients with
multivessel disease (N-IRA lesions of >50 % diameter steno-
sis) in a 2:1 fashion to receive either early FFR-guided
revascularisation of N-IRA lesions or to conservative medical
treatment [39]. Randomisation occurred following successful
primary PCI of the culprit lesion. Repeat angiography in the
invasive group was performed at a median of 7.5 days after
primary PCI.
Of the 80 patients allocated to the invasive treatment arm,
only 65 underwent FFR assessment of non-culprit lesions.
From these, 42 patients (50 lesions) demonstrated positive
FFR measurement, with 23 patients (41 lesions) with negative
FFR and hence managed conservatively.
At 6 months, there was no difference in MACE rates
(death/MI/repeat PCI) between the two strategies using an
intention-to-treat analysis (16 vs. 22 %, P=0.292). A pre-
specified per protocol analysis showed significantly higher
rates of repeat PCI in the culprit-only group (6 vs. 22 %, P=
0.017), with death and MI occurring solely in the FFR-guided
revascularisation group, leading to comparable 6-month com-
posite MACE rates (14 vs. 22 %, P=0.292). A longer-term
follow-up to 3 years of these patients showed no significant
difference in all-cause mortality between invasive and conser-
vatively managed groups, higher rate of death and non-fatal
MI with the invasively treated group (13.4 % all in the inva-
sive group, P=0.002); however, lower rate of PCI in non-
culprit vessel in the invasive group (8.9 vs. 32.5 %, P=
0.001). There was no difference in MACE between the two
groups (35 vs. 35 %, P=0.896) [40]; however, the study was
not powered to detect difference in MACE.
DANAMI3-PRIMULTI also employed FFR as a means of
selecting N-IRA lesions for intervention. There was a signif-
icant reduction in MACE event rates with complete
revascularisation, driven mainly by a reduction in ischaemia-
driven revascularisation in the complete revascularisation arm
[31]. However, no assessment was made of the haemodynam-
ic significance of N-IRA lesions in the medically managed
group.
None of the above studies addresses the question of
whether FFR provides a more sensitive means of determin-
ing which N-IRA lesions should be intervened upon com-
pared to assessment by angiographic significance. The
COMPARE-ACUTE trial (NCT01399736) is currently on-
going and will recruit 885 patients, comparing FFR-guided
complete revascularisation with culprit-only PCI. This
study will also compare MACE outcomes as one of the
subgroup analyses staged PCI to N-IRA lesions that are
angiographically significant (DS >50 %) but with a nega-
tive FFR with not intervening on these lesions.
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While clearly there is evidence to support use of FFR in
determining significant flow-limiting lesions in stable angina,
one aspect with regard to N-IRA lesions in STEMI is that they
may represent a more vulnerable plaque morphology com-
pared to stable angina patients, and hence outcomes may not
solely be driven by the haemodynamic significance of the
lesion. Analysis non-culprit lesions of ACS patients using
VH-IVUS has shown a greater proportion of vulnerable
plaques, with greater proportion of necrotic core and thin-
cap fibroatheroma compared with stable coronary lesions
[41]. TCFA lesions were also seen in 46.7 % of non-culprit
lesions within ACS population from the PROSPECT study;
logistic regression demonstrated the presence of TCFA at non-
culprit site was an independent predictor of future MACE
events [42].
Similarly, Kato et al. [43•] have demonstrated differences
in plaque composition in non-culprit lesions from ACS pa-
tients compared to stable angina plaques using three-vessel
OCT. Specifically, non-culprit plaques demonstrated wider
lipid arc (147.3±29.5° versus 116.2±33.7°, P<0.001), a lon-
ger lipid length (10.7±5.9 versus 7.0±3.7 mm, P=0.002), a
larger lipid volume index [averaged lipid arc×lipid length]
(1605.5±1013.1 versus 853.4±570.8, P<0.001) and a thinner
fibrous cap (70.2±20.2 versus 103.3±46.8 μm, P<0.001).
Also, there was a higher prevalence of TCFA in non-culprit
ACS lesions compared to stable angina patients. These find-
ings suggest that non-culprit plaques in ACS patients are in-
herently more vulnerable and may account for recurrent isch-
aemic events occurring after the primary event at these sites.
Hence, one could hypothesise that in the context of STEMI
and multivessel disease, plaque morphology in addition to
haemodynamic significance, should drive decision making
in terms of N-IRA PCI. Further studies using VH-IVUS or
OCT to determine plaque composition in N-IRA lesions and
impact of this on preventing futureMACE events, particularly
hard endpoint of non-fatal MI, would be required. Findings
from intracoronary near infra-red spectroscopy have identified
plaques with large lipid cores at culprit sites for STEMI and
NSTEMI [44, 45]. This may also provide a useful tool for site-
specific identification of N-IRA plaques that may give rise to
future coronary events; however, this hypothesis would also
require validation in large prospective randomised studies.
Conclusions
The recently reported PRAMI, CvLPRIT and DANAMI3-
PRIMULTI randomised controlled trials have shown that in
patients presenting with STEMI and evidence of additional
non-infarct-related artery lesions, a strategy of complete
revascularisation results appears to result in improved clinical
outcomes compared with culprit-only PCI. These studies shed
new light on the management of such patients, as previous
studies were non-randomised and retrospective in nature. In
addition, these RCTs reflect more contemporary clinical prac-
tice with regard to use of drug-eluting stents, radial access as
the preferred vascular approach and use of newer generation
P2Y12 inhibitors such as Prasugrel and Ticagrelor, all of which
may add towards the improved clinical outcomes seen com-
pared to previous trials.
There however remain unanswered questions with regard
to the optimal management strategy of STEMI patients with
multivessel disease. The timing of intervention in N-IRA ar-
teries remains unclear, with current data presenting conflicting
evidence in terms of whether same sitting, same admission or
staged procedures would result in improved outcomes. Anoth-
er issue is the optimal method of determining which N-IRA
lesions require intervention, either by angiographic severity or
use of FFR to guide intervention based on haemodynamic
significance of N-IRA lesions.
Finally, although the recently reported RCTs demonstrate
improved MACE outcomes with complete revascularisation,
these are mostly driven by ischaemic-driven revascularisation
and MI in the case of PRAMI. Hence, larger studies powered
to detect differences in hard clinical endpoints of death andMI
are required.
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